摘要
目的探讨对索拉非尼治疗效果不佳的中晚期肝癌患者采用安罗替尼靶向治疗的临床效果。方法选取2018年8月—2019年10月河南省某医院收治的20例中晚期肝癌患者为研究对象。给予患者口服安罗替尼12 mg,1次/d,连续服用14 d后停用1周。21 d为1个疗程。患者均每6周通过复查CT或核磁共振评价疗效1次,根据CT或核磁共振测量的目标病灶最大直径判断治疗效果。观察患者的治疗效果、生存情况、不良反应发生情况。结果1例(5%)达到部分缓解(PR),9例(45%)为疾病稳定(SD),10例(50%)出现疾病进展(PD)。无进展生存(PFS)为4.2个月(95%CI:2.8~5.7个月),总生存(OS)为9.6个月(95%CI:8.5~10.6个月)。没有发生因严重不良反应导致的治疗终止事件,且未观察到治疗相关死亡事件。不良反应有手足综合征(4/20,20%),高血压(6/20,30%),蛋白尿(3/20,15%),乏力(9/20,45%),腹泻(3/20,15%),消化道出血(1/20,5%),经对症治疗后均得到有效控制。结论给予索拉非尼治疗效果不佳的中晚期肝癌患者安罗替尼单药治疗,临床效果显著,不良事件发生率低,生存期较长,可作为中晚期肝癌患者后线治疗的抉择。
Objective To explore the clinical effects of targeted therapy with anlotinib in patients with intermediate to advanced hepatocellular carcinoma who had poor results with sorafenib treatment.Methods Twenty patients with intermediate to advanced hepatocellular carcinoma admitted to a hospital in Henan Province from August 2018 to October 2019 were selected for the study.Patients were given oral anlotinib 12 mg,1 time/d,for 14 d and then stopped for 1 week.21 d was 1 course of treatment.Patients were reviewed every 6 weeks by CT or MRI to evaluate the efficacy,and the treatment effect was judged according to the maximum diameter of the target lesion measured by CT or MRI.The patients were observed for treatment effect,survival,and occurrence of adverse effects.Results One case(5%)achieved partial remission(PR),9 cases(45%)had stable disease(SD),and 10 cases(50%)showed disease progression(PD).Progression-free survival(PFS)was 4.2 months(95%CI:2.8-5.7 months)and overall survival(OS)was 9.6 months(95%CI:8.5-10.6 months).There were no treatment discontinuations due to serious adverse reactions,and no treatment-related deaths were observed.The adverse reactions were hand-foot syndrome(4/20,20%),hypertension(6/20,30%),proteinuria(3/20,15%),malaise(9/20,45%),diarrhea(3/20,15%),and gastrointestinal bleeding(1/20,5%),and all were effectively controlled with symptomatic treatment.Conclusion Anlotinib monotherapy given to patients with intermediate to advanced hepatocellular carcinoma who had poor results with sorafenib had significant clinical effects,low incidence of adverse events,and long survival,and can be used as a choice of post-line therapy for patients with intermediate to advanced hepatocellular carcinoma.
作者
王新亭
陈晓琦
张传雷
陈欣菊
Wang Xinting;Chen Xiaoqi;Zhang Chuanlei;Chen Xinju(Department of Gastroenterology,The First Affiliated Hospital of Henan University of Traditional Chinese Medicine,Zhengzhou 450000,China)
出处
《保健医学研究与实践》
2021年第6期48-50,共3页
Health Medicine Research and Practice
基金
国家科技重大专项基金(2018ZX10303-502)。
关键词
肝癌
分子靶向治疗
安罗替尼
治疗效果
Hepatocellular carcinoma
Molecular targeted therapy
Anlotinib
Treatment effect
